Colon Cancer

NT5E accelerates disease progression by promoting malignant biological behaviors in colorectal cancer and synergistically shaping an immunosuppressive microenvironment with PD-L1. Its overexpression constitutes an independent adverse prognostic factor. This discovery offers novel insights for anti-PD-1/PD-L1 combination immunotherapy.

P2, N=26, Not yet recruiting, Northwell Health

Liver lesions shrank after treatment with octreotide and Lutetium-177 vipivotide tetraxetan...The role of microsatellite instability (MSI) as a screening marker, and personalized treatment approaches like immunotherapy for dMMR tumors. Understanding these correlations may assist in early discovery, surveillance, and customized treatment for patients dealing with LS-associated malignancies.

Postoperative circulating tumor DNA was negative, and the patient was placed on active surveillance; however, neurological symptoms persisted, and immunomodulatory therapy access was initially limited. This case highlights a rare association between anti-Hu-associated myeloneuropathy and early-onset colon cancer and underscores the importance of malignancy evaluation in unexplained sensory neuronopathy.

Even though this molecule is two-fold less active than reference drug 5-fluorouracil (5-FU), the pharmacophore of the compound 10d would be considered for future derivatisation as a notable anticancer agent, due to its safety profile against normal cell line HEK...The compound 10d demonstrated the greatest affinity for both targets (- 8.8 and - 7.9 kcal/mol, respectively), whereas other compounds showed favourable binding energies. These findings suggest that compound 10d may serve as a promising lead for further biological evaluation.

PRONano is brain-targeted, rationally designed nanoformulation which can overcome major A1874 delivery constraints. This strategy augmented PROTAC delivery and therapeutic potential in GBM, supporting future preclinical development.

Intriguingly, RBPJ upregulation counteracts HP1γ-induced hyperproliferation, implicating HP1γ as a critical modulator of Notch signaling. Our findings establish HP1γ as a promoter of CRC progression through suppression of Notch pathway components, highlighting its potential as a diagnostic marker or therapeutic target in CRC.

P1/2, N=482, Recruiting, BioNTech SE | Trial completion date: May 2031 --> Dec 2032

P1, N=51, Completed, The University of Texas Health Science Center at San Antonio | Active, not recruiting --> Completed

P=N/A, N=5000, Recruiting, Dana-Farber Cancer Institute

FUT2 promotes colon cancer cell differentiation by mediating OLFM4 fucosylation, suggesting that FUT2 may serve as a therapeutic target for colon cancer.

Fluorescence in situ hybridization (FISH) revealed EWSR1 gene rearrangement, and next-generation sequencing (NGS)-based RNA fusion gene detection identified EWSR1::ATF1 fusion, supporting the diagnosis of MGNET. We will discuss the abnormal immunophenotype and differential diagnosis of MGNET, reviewing relevant literature.